trial

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

NCTId NCT05227703
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 391 (actual)
Sponsored by AbbVie
Primary completion 2024-08-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
391 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2022-07-05
Primary completion
2024-08-15
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Emraclidine

Sponsors

AbbVieLead Sponsor

Investigators

1
Julie AdamsStudy Director

Sites

26 total
Bentonville, United StatesBellflower, United StatesLa Habra, United StatesSan Diego, United StatesSherman Oaks, United StatesTorrance, United StatesNew Haven, United StatesHomestead, United StatesMiami, United StatesMiami Lakes, United StatesMiami Springs, United StatesAtlanta, United States

Linked catalysts

1
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schi — primary completion2024-08-15

Facts & assertions

4 sourced
Enrollment
391
Phase
PHASE2
Primary Completion Date
2024-08-15
Status
COMPLETED
relationships
The graph out of here
drug
Emraclidine
drug
lead_sponsor
AbbVie
company
indication
Schizophrenia
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Schizophrenia
indication
investigator
Julie Adams
person